EFM
KYTX icon

E Fund Management’s Kyverna Therapeutics KYTX Stock Holding History

E Fund Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-189,432
Closed -$926K – 415
2024
Q3 		$926K Hold
189,432
– – 0.05% 150
2024
Q2 		$1.42M Buy
+189,432
New +$2.89M 0.08% 99

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

E Fund Management's KYTX Position: Q4 2024 in Review

E Fund Management sold out of Kyverna Therapeutics (KYTX) in Q4 2024, closing a stake of 189,432 shares — an estimated $926K sold.

E Fund Management first reported a position in KYTX in Q2 2024 and held it in 2 quarters. The position peaked at $1.42M in Q2 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q4 2024.

  • E Fund Management reported no remaining Kyverna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • E Fund Management sold 189,432 Kyverna Therapeutics shares in Q4 2024, an estimated $926K.
  • E Fund Management first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 2 quarters.
  • E Fund Management's Kyverna Therapeutics position peaked at $1.42M in Q2 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2024.

Based on E Fund Management's 13F filing for Q4 2024, filed 7 Feb 2025.